VERV
Closed
Verve Therapeutics Inc
5.595
+0.065 (+1.18%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 5.53
Day's Range: 5.15 - 5.735
Send
sign up or login to leave a comment!
When Written:
13.99
Verve Therapeutics Inc is a biotechnology company that is focused on developing innovative gene-editing therapies for the treatment of cardiovascular diseases. The company was founded in 2019 by a team of world-renowned scientists, including Dr. Sekar Kathiresan, Dr. Kiran Musunuru, Dr. J. Keith Joung, and Dr. Andrew Bellinger.
Verve Therapeutics is developing gene-editing therapies that target specific genes associated with cardiovascular disease, including PCSK9, ANGPTL3, and APOC3. The company's lead product candidate is VERVE-101, which is a gene-editing therapy designed to reduce the risk of heart disease by lowering levels of the PCSK9 protein.
Verve Therapeutics has raised over $300 million in funding from investors, including GV, ARCH Venture Partners, and Biomatics Capital. The company is headquartered in Cambridge, Massachusetts, and has a team of over 70 employees.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Verve Therapeutics is developing gene-editing therapies that target specific genes associated with cardiovascular disease, including PCSK9, ANGPTL3, and APOC3. The company's lead product candidate is VERVE-101, which is a gene-editing therapy designed to reduce the risk of heart disease by lowering levels of the PCSK9 protein.
Verve Therapeutics has raised over $300 million in funding from investors, including GV, ARCH Venture Partners, and Biomatics Capital. The company is headquartered in Cambridge, Massachusetts, and has a team of over 70 employees.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!